ki16425  (Echelon Biosciences)


Bioz Verified Symbol Echelon Biosciences is a verified supplier
Bioz Manufacturer Symbol Echelon Biosciences manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85

    Structured Review

    Echelon Biosciences ki16425
    ]. LPA (1 µmol/l) or BVi was added for 2 days; the treatments were renewed every 12 h. The vessel length was measured before and after the indicated treatments. Data shown are the means±SEM of four independent experiments. ( a ) Treatment with BVi induced regression comparable with that mediated by LPA. Addition of the LPA receptor inhibitors BrP-LPA (10 µmol/l) or <t>Ki16425</t> (5 µmol/l) in combination with BVi inhibited regression. Addition of the inhibitors alone had no effect. The percentage stability is the ratio of vessel lengths before and after treatment. * p
    Ki16425, supplied by Echelon Biosciences, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ki16425/product/Echelon Biosciences
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ki16425 - by Bioz Stars, 2022-08
    85/100 stars

    Images

    1) Product Images from "Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy"

    Article Title: Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy

    Journal: Diabetologia

    doi: 10.1007/s00125-013-2884-2

    ]. LPA (1 µmol/l) or BVi was added for 2 days; the treatments were renewed every 12 h. The vessel length was measured before and after the indicated treatments. Data shown are the means±SEM of four independent experiments. ( a ) Treatment with BVi induced regression comparable with that mediated by LPA. Addition of the LPA receptor inhibitors BrP-LPA (10 µmol/l) or Ki16425 (5 µmol/l) in combination with BVi inhibited regression. Addition of the inhibitors alone had no effect. The percentage stability is the ratio of vessel lengths before and after treatment. * p
    Figure Legend Snippet: ]. LPA (1 µmol/l) or BVi was added for 2 days; the treatments were renewed every 12 h. The vessel length was measured before and after the indicated treatments. Data shown are the means±SEM of four independent experiments. ( a ) Treatment with BVi induced regression comparable with that mediated by LPA. Addition of the LPA receptor inhibitors BrP-LPA (10 µmol/l) or Ki16425 (5 µmol/l) in combination with BVi inhibited regression. Addition of the inhibitors alone had no effect. The percentage stability is the ratio of vessel lengths before and after treatment. * p

    Techniques Used:

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85
    Echelon Biosciences ki16425
    ]. LPA (1 µmol/l) or BVi was added for 2 days; the treatments were renewed every 12 h. The vessel length was measured before and after the indicated treatments. Data shown are the means±SEM of four independent experiments. ( a ) Treatment with BVi induced regression comparable with that mediated by LPA. Addition of the LPA receptor inhibitors BrP-LPA (10 µmol/l) or <t>Ki16425</t> (5 µmol/l) in combination with BVi inhibited regression. Addition of the inhibitors alone had no effect. The percentage stability is the ratio of vessel lengths before and after treatment. * p
    Ki16425, supplied by Echelon Biosciences, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ki16425/product/Echelon Biosciences
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ki16425 - by Bioz Stars, 2022-08
    85/100 stars
      Buy from Supplier

    Image Search Results


    ]. LPA (1 µmol/l) or BVi was added for 2 days; the treatments were renewed every 12 h. The vessel length was measured before and after the indicated treatments. Data shown are the means±SEM of four independent experiments. ( a ) Treatment with BVi induced regression comparable with that mediated by LPA. Addition of the LPA receptor inhibitors BrP-LPA (10 µmol/l) or Ki16425 (5 µmol/l) in combination with BVi inhibited regression. Addition of the inhibitors alone had no effect. The percentage stability is the ratio of vessel lengths before and after treatment. * p

    Journal: Diabetologia

    Article Title: Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy

    doi: 10.1007/s00125-013-2884-2

    Figure Lengend Snippet: ]. LPA (1 µmol/l) or BVi was added for 2 days; the treatments were renewed every 12 h. The vessel length was measured before and after the indicated treatments. Data shown are the means±SEM of four independent experiments. ( a ) Treatment with BVi induced regression comparable with that mediated by LPA. Addition of the LPA receptor inhibitors BrP-LPA (10 µmol/l) or Ki16425 (5 µmol/l) in combination with BVi inhibited regression. Addition of the inhibitors alone had no effect. The percentage stability is the ratio of vessel lengths before and after treatment. * p

    Article Snippet: The pan-LPA receptor antagonist 1-bromo-3(S)-hydroxy-4-[(palmitoyloxy)butyl] phosphonate (BrP-LPA) and Ki16425 were from Echelon Biosciences (Salt Lake City, UT, USA) and Cayman Chemical (Ann Arbor, MI, USA), respectively.

    Techniques: